Improving Stratification for Children With Late Bone Marrow B-Cell Acute Lymphoblastic Leukemia Relapses With Refined Response Classification and Integration of Genetics
Cornelia Eckert, Stefanie Groeneveld-Krentz, Renate Kirschner-Schwabe, Nikola Hagedorn, Christiane Chen-Santel, Peter Bader, Arndt Borkhardt, Gunnar Cario, Gabriele Escherich, Renate Panzer-Grümayer, Kathy Astrahantseff, Angelika Eggert, Lucie Sramkova, Andishe Attarbaschi, Jean-Pierre Bourquin, Christina Peters, Günter Henze, Arend von Stackelberg, ALL-REZ BFM Trial Group, Cornelia Eckert, Stefanie Groeneveld-Krentz, Renate Kirschner-Schwabe, Nikola Hagedorn, Christiane Chen-Santel, Peter Bader, Arndt Borkhardt, Gunnar Cario, Gabriele Escherich, Renate Panzer-Grümayer, Kathy Astrahantseff, Angelika Eggert, Lucie Sramkova, Andishe Attarbaschi, Jean-Pierre Bourquin, Christina Peters, Günter Henze, Arend von Stackelberg, ALL-REZ BFM Trial Group
Abstract
Purpose: Minimal residual disease (MRD) helps to accurately assess when children with late bone marrow relapses of B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) will benefit from allogeneic hematopoietic stem-cell transplantation (allo-HSCT). More detailed dissection of MRD response heterogeneity and the specific genetic aberrations could improve current practice.
Patients and methods: MRD was assessed after induction treatment and at different times during relapse treatment until allo-HSCT (indicated in poor responders to induction; MRD ≥ 10-3) for patients being treated for late BCP-ALL bone marrow relapses (n = 413; median follow-up, 9.4 years) in the ALL-REZ BFM 2002 trial/registry (ClinicalTrials.gov identifier: NCT00114348).
Results: Patients with both good (MRD < 10-3) and poor responses to induction treatment reached excellent event-free survival (EFS; 72% v 65%) and overall survival (OS; 82% v 74%). Patients with MRD of 10-2 or greater after induction had reduced EFS (56%), and their MRD persisted until allo-HSCT more frequently than it did in patients with MRD of 10-3 or greater to less than 10-2 (P = .037). Patients with 25% or more leukemic blasts after induction (early nonresponders) had the poorest prognosis (EFS, 22%). Interestingly, patients with MRD of 10-3 or greater before allo-HSCT (late nonresponders) still had an EFS of 50% and OS of 63%, which in principle justifies allo-HSCT in these patients. From a panel of selected candidate genes, TP53 alterations (frequency, 8%) were the only genetic alteration with independent prognostic value in any MRD-based response subgroup.
Conclusion: After induction treatment, MRD-based treatment stratification resulted in excellent survival in patients with late relapsed BCP-ALL. Prognosis could be further improved in very poor responders by intensifying treatment directly after induction. TP53 alterations can be defined as a novel genetic high-risk marker in all MRD response groups in late relapsed BCP-ALL. Here we identified early and late nonresponders to be considered as events in future trials.
Source: PubMed